Back to results

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

Primary Purpose

Carcinoid Tumor

Status

Completed

Phase

Phase 2

Locations

United States

Study Type

Interventional

Intervention

Ziv-aflibercept

About this trial

This is an interventional treatment trial for Carcinoid Tumor focused on measuring Progressive, Metastatic

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Histologically confirmed well differentiated or moderately differentiated neuroendocrine tumor from either a primary or metastatic site
Must have disease that is not amenable to curative resection
Must have evidence of disease progression within 12 months prior to study entry
Must have measurable disease (RECIST 1.1)
Prior chemoembolization of local ablative therapies are allowed, provided there is measurable disease outside of the area treated, or documented evidence of progression at the site of prior treatment
No limit to number of prior treatments. Prior bevacizumab allowed unless discontinued due to unacceptable toxicity. Prior TKI targeting VEGF receptors allowed
Treatment with a somatostatin analog required for all subjects
Subjects with history of hypertension must be adequately controlled
Therapeutic anticoagulation is allowed. Must be on a stable dose of anticoagulant medication
Must agree to use adequate contraception prior to study entry, for the duration of study participation and for 3 months after last administration of study drug

Exclusion Criteria:

Prior treatment including chemoembolization within 4 weeks of study entry
Major surgery within 4 weeks of study entry or minor surgery within 2 weeks of study entry
Pregnant or breastfeeding
Poorly differentiated carcinoma, high grade neuroendocrine tumor or small cell carcinoma
Prior treatment with Ziv-aflibercept
Pancreatic neuroendocrine tumor (islet cell carcinoma)will be excluded from this study. All non functional and functional islet cell carcinomas such as insulinoma, glucagonoma, gastrinoma, VIPoma will be excluded.
Not adequately recovered from toxicity of previous therapy
Known untreated brain or other central nervous system metastases
Known allergy to any of the study agents or to compounds of similar chemical or biologic composition
History of congestive heart failure
Symptomatic peripheral arterial disease
Unhealed wounds, ulcers or bone fractures
HIV positive or active Hepatitis infection
History of abdominal fistula, GI perforation, intra abdominal abscess, uncontrolled GI bleeding, diverticulitis within 6 months of study entry
History of arterial thrombotic events such as myocardial infarction, unstable angina pectoris or any ischemic or hemorrhagic cerebrovascular accident within the past 6 months
No history of pulmonary embolism, DVT or vascular access related thrombosis if not also receiving adequate anticoagulation at a stable dose.
No history of prior or synchronous malignancy except if treated with curative intent at least 3 years prior to study entry, or adequately treated non-melanoma skin cancer, cervical carcinoma in situ, or prostate intraepithelial neoplasia without evidence of prostate cancer
Uncontrolled non-malignant illness that may increase the risks associated with study participation or may interfere with the conduct of the study or interpretation of study results
Uncontrolled psychiatric illness or social situations that would limit compliance with study requirements

Sites / Locations

Massachusetts General Hospital
Brigham and Women's Hospital
Dana-Farber Cancer Institute

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Experimental Treatment Arm

Arm Description

Ziv-aflibercept IV every 2 weeks, 4 mg/kg

Outcomes

Primary Outcome Measures

Progression Free Survival

To evaluate the progression-free survival (PFS) duration of patients with metastatic, unresectable, progressive carcinoid tumors treated with Ziv-aflibercept. Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) was used. Progressive Disease (PD) is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study with at least a 5 mm absolute increase in the sum of all lesions. The appearance of one or more new lesions denotes disease progression. Partial Response (PR) is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.

Secondary Outcome Measures

Evaluation of Disease Response

To evaluate disease response using RECIST criteria, version 1.1, of patients with advanced carcinoid tumors treated with Ziv-aflibercept. Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI or CT include the following categories of disease response: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable disease (SD), less than 30% decrease but no more than 20% increase in sum of the longest diameter of target lesions.

Evaluation of Biochemical Response - Number of Patients With Greater Than 50% Drop in Chromogranin A From Baseline

To evaluate biochemical response in patients with elevated chromogranin A at baseline, using levels of chromogranin-A measured at baseline and following treatment with Ziv-aflibercept. Biochemical response was defined as greater than 50% drop in chromogranin A from baseline. During the screening period, all patients were evaluated for serum chromogranin A. Per protocol, if results of these are normal at baseline, they were not repeated while on study. If above institutional ULN at baseline, they were evaluated at time of tumor restaging.

Biochemical Response - Number of Patients With Greater Than 50% Drop in 24hr Urine 5-HIAA From Baseline

To evaluate biochemical response in patients with elevated 24hr urine 5-HIAA at baseline, using levels of 24hr urine 5-HIAA at baseline and following treatment with Ziv-aflibercept. Biochemical response was defined as greater than 50% drop in 24hr urine 5-HIAA from baseline. During the screening period, all patients were evaluated for 24hr urine 5HIAA. Per protocol, if results of these were normal at baseline, they were not repeated while on study. If above institutional ULN at baseline, they were evaluated at time of tumor restaging.

Full Information

NCT ID

NCT01782443

First Posted

January 31, 2013

Last Updated

August 11, 2023

Sponsor

Dana-Farber Cancer Institute

1. Study Identification

Unique Protocol Identification Number

NCT01782443

Brief Title

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

Official Title

Phase II Study of Ziv-aflibercept in Patients With Advanced, Progressive Carcinoid Tumors

Study Type

Interventional

2. Study Status

Record Verification Date

August 2023

Overall Recruitment Status

Completed

Study Start Date

February 13, 2013 (Actual)

Primary Completion Date

March 2021 (Actual)

Study Completion Date

December 26, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Principal Investigator

Name of the Sponsor

Dana-Farber Cancer Institute

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. "Investigational" means that the drug, Ziv-aflibercept, is being studied. It also means that the FDA has not yet approved Ziv-aflibercept for use in patients with your type of cancer. Every person has molecules in their bloodstream called vascular endothelial growth factors (VEGFs). These molecules help grow and sustain new blood vessels needed by the human body. Cancer tumors hijack this mechanism because they need new blod vessels and oxygen to grow. Ziv-aflibercept is an antibody. Antibodies are proteins that are produced naturally in our bodies and help to recognize foreign substances in our body. Ziv-aflibercept is a "targeted therapy" called a "VEGF Trap", that "traps" (binds) these VEGFs and prevents the cancer from using them to grow. Though Ziv-aflibercept has not yet been FDA approved for the treatment of carcinoid tumors, it has recently been approved for patients with treatment-resistant colorectal cancer. In this research study, we will use Ziv-aflibercept in combination with standard octreotide therapy to see if it slows the growth or spread of your carcinoid tumor. Standard octreotide (sandostatin) therapy is currently approved for treating symptoms of carcinoid tumors, such as those caused by carcinoid syndrome. Carcinoid syndrome is caused by hormones and other substances released by carcinoid tumors into the bloodstream. One of these secreted substances is serotonin, one of the body's natural chemical messengers. When excess serotonin secreted by the carcinoid tumors reaches the body's tissues, it is thought to cause diarrhea and redness (flushing) of the face, chest or back. Excess serotonin may also cause changes in the structure of the heart valves, which can impair the heart's function. Octreotide works by binding to receptors found on carcinoid tumors and prevents the release of hormones from the tumor.

Detailed Description

If you are willing to participate in this study you will be asked to undergo some screening tests and procedures to confirm that you are eligible. Many of these tests and procedures are likely to be part of regular cancer care and may be done even if it turns out that you do not take part in the research study. If you have had some of these tests or procedures recently, they may or may not have to be repeated. These tests and procedures include: a medical history, physical examination, CT or MRI, blood tests, serum chromogranin A, urine tests, 24-hour urine collection, pregnancy test and an electrocardiogram. If these tests show that you are eligible to participate in the research study, you will begin the study treatment. If you do not meet the eligibility criteria, you will not be able to participate in this research study. If you meet the requirements for this study and you agree to continue your participation, you will receive Ziv-aflibercept every two weeks. Each dose of Ziv-aflibercept consists of an approximately 60 minutes infusion (through a needle into a vein). You will also receive an injection of Octreotide LAR (long acting release) monthly as part of your treatment for carcinoid tumor. This injection will be given to you by a nurse in your buttock. You may already be on Octreotide LAR. In that case, you will continue taking it at the same dose and schedule. You will need to come to the clinic every two weeks while participating in this study. Each cycle is 28 days. The following tests and procedures will be performed on Days 1 and 15 of each cycle: questions about your health, physical exam (Day 1 of each cycle only), vital signs, blood tests, pregnancy test (Day 1 of each cycle only). Urine tests will be performed every other cycle. The following tests and procedures will be done at the end of every third cycle: CT scan or MRI, Serum Chromogranin A, 24-hour urine collection. After the final dose of the study drug the following tests and procedures will be performed: questions about your general health, physical exam, vital signs, blood tests, pregnancy test, EKG, Serum Chromogranin A, 24-hour urine collection.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Carcinoid Tumor

Keywords

Progressive, Metastatic

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

19 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Experimental Treatment Arm

Arm Type

Experimental

Arm Description

Ziv-aflibercept IV every 2 weeks, 4 mg/kg

Intervention Type

Drug

Intervention Name(s)

Ziv-aflibercept

Primary Outcome Measure Information:

Title

Progression Free Survival

Description

Time Frame

2 years

Secondary Outcome Measure Information:

Title

Evaluation of Disease Response

Description

Time Frame

2 years

Title

Evaluation of Biochemical Response - Number of Patients With Greater Than 50% Drop in Chromogranin A From Baseline

Description

Time Frame

2 years

Title

Biochemical Response - Number of Patients With Greater Than 50% Drop in 24hr Urine 5-HIAA From Baseline

Description

Time Frame

2 years

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Histologically confirmed well differentiated or moderately differentiated neuroendocrine tumor from either a primary or metastatic site Must have disease that is not amenable to curative resection Must have evidence of disease progression within 12 months prior to study entry Must have measurable disease (RECIST 1.1) Prior chemoembolization of local ablative therapies are allowed, provided there is measurable disease outside of the area treated, or documented evidence of progression at the site of prior treatment No limit to number of prior treatments. Prior bevacizumab allowed unless discontinued due to unacceptable toxicity. Prior TKI targeting VEGF receptors allowed Treatment with a somatostatin analog required for all subjects Subjects with history of hypertension must be adequately controlled Therapeutic anticoagulation is allowed. Must be on a stable dose of anticoagulant medication Must agree to use adequate contraception prior to study entry, for the duration of study participation and for 3 months after last administration of study drug Exclusion Criteria: Prior treatment including chemoembolization within 4 weeks of study entry Major surgery within 4 weeks of study entry or minor surgery within 2 weeks of study entry Pregnant or breastfeeding Poorly differentiated carcinoma, high grade neuroendocrine tumor or small cell carcinoma Prior treatment with Ziv-aflibercept Pancreatic neuroendocrine tumor (islet cell carcinoma)will be excluded from this study. All non functional and functional islet cell carcinomas such as insulinoma, glucagonoma, gastrinoma, VIPoma will be excluded. Not adequately recovered from toxicity of previous therapy Known untreated brain or other central nervous system metastases Known allergy to any of the study agents or to compounds of similar chemical or biologic composition History of congestive heart failure Symptomatic peripheral arterial disease Unhealed wounds, ulcers or bone fractures HIV positive or active Hepatitis infection History of abdominal fistula, GI perforation, intra abdominal abscess, uncontrolled GI bleeding, diverticulitis within 6 months of study entry History of arterial thrombotic events such as myocardial infarction, unstable angina pectoris or any ischemic or hemorrhagic cerebrovascular accident within the past 6 months No history of pulmonary embolism, DVT or vascular access related thrombosis if not also receiving adequate anticoagulation at a stable dose. No history of prior or synchronous malignancy except if treated with curative intent at least 3 years prior to study entry, or adequately treated non-melanoma skin cancer, cervical carcinoma in situ, or prostate intraepithelial neoplasia without evidence of prostate cancer Uncontrolled non-malignant illness that may increase the risks associated with study participation or may interfere with the conduct of the study or interpretation of study results Uncontrolled psychiatric illness or social situations that would limit compliance with study requirements

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Jennifer Chan, MD

Organizational Affiliation

Dana-Farber Cancer Institute

Official's Role

Principal Investigator

Facility Information:

Facility Name

Massachusetts General Hospital

City

Boston

State/Province

Massachusetts

ZIP/Postal Code

02115

Country

United States

Facility Name

Brigham and Women's Hospital

City

Boston

State/Province

Massachusetts

ZIP/Postal Code

02215

Country

United States

Facility Name

Dana-Farber Cancer Institute

City

Boston

State/Province

Massachusetts

ZIP/Postal Code

02215

Country

United States

12. IPD Sharing Statement

Citations:

PubMed Identifier

36395401

Citation

Perez K, Kulke MH, Horick NK, Regan E, Graham C, Scheutz S, Stonely D, Enzinger PC, Fuchs CS, Allen JN, Enzinger AC, Clark JW, Chan JA. A Phase II Study of Ziv-Aflibercept in Patients With Advanced Extrapancreatic Neuroendocrine Tumors. Pancreas. 2022 Aug 1;51(7):763-768. doi: 10.1097/MPA.0000000000002099.

Results Reference

derived

Learn more about this trial

Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors

We'll reach out to this number within 24 hrs